The U.S. Food and Drug Administration (FDA) has announced meetings to reconsider a ban on 12 unproven peptides that were deemed to pose significant safety risks in 2023. These meetings, scheduled for two days in July and another in February 2027, are being held in response to pressure from Health Secretary Robert F. Kennedy Jr., who has publicly supported the use of these peptides despite their lack of scientific validation. Peptides are short chains of amino acids, and while some are FDA-approved for conditions like diabetes and obesity, the unproven variants are often marketed for anti-aging and other health benefits without any supporting evidence. Kennedy, who has no formal background in science or medicine, claims to have used these substances effectively for injuries and has vowed to end the FDA's restrictions on them. However, skepticism remains among experts regarding the FDA's ability to evaluate these drugs effectively, especially considering the advisory panel, the Pharmacy Compounding Advisory Committee (PCAC), currently has only three voting members and several vacancies.